Label: ZUPREVO- tildipirosin injection, solution

  • NDC Code(s): 0061-4321-01, 0061-4321-02, 0061-4321-03
  • Packager: Merck Sharp & Dohme Corp.
  • Category: PRESCRIPTION ANIMAL DRUG LABEL

Drug Label Information

Updated November 22, 2023

If you are a healthcare professional or from the pharmaceutical industry please visit this version.

View All Sections
  • SPL UNCLASSIFIED SECTION

    397457 R1

  • SPL UNCLASSIFIED SECTION

    Antimicrobial Drug

    180 mg of tildipirosin/mL

    For subcutaneous injection in beef and non-lactating dairy cattle only.

    Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

  • CAUTION:

    Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

  • DESCRIPTION:

    Zuprevo™18% is a ready-to-use sterile injectable solution containing tildipirosin, a semi-synthetic macrolide antibiotic. Each mL of Zuprevo™18% contains 180 mg of tildipirosin as the free base, 82.5 mg citric acid monohydrate and 400 mg propylene glycol, and water qs with citric acid monohydrate added to adjust pH.

    CHEMICAL NOMENCLATURE AND STRUCTURE: Tildipirosin is the nonproprietary name for (11E,13E)-(4R,5S,6S,7R,9R,15R,16R)-6-(4-Dimethylamino-3,5-dihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-(2-piperidin-1-yl-ethyl)-15-piperidin-1-ylmethyl-oxacyclohexadeca-11,13-diene-2,10-dione. The empirical formula is C41H71N3O8. The chemical structure of tildipirosin is shown below.

    Figure 1

    Chemical Structure

  • VETERINARY INDICATIONS

    INDICATIONS: Zuprevo™18% is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef and and non-lactating dairy cattle, and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni.

  • DOSAGE & ADMINISTRATION

    DOSAGE AND ADMINISTRATION: Inject subcutaneously as a single dose in the neck at a dosage of 4 mg/kg (1 mL/100 lb) body weight (BW). Do not inject more than 10 mL per injection site. Do not puncture the stopper of the respective vial size more than the tested number of punctures, shown in Table 1.

    Clinical field studies indicate that administration of Zuprevo™ 18% (tildipirosin) Injectable Solution is effective for the control of respiratory disease in beef and non-lactating dairy cattle at "high risk" of developing BRD. Calves at high risk of developing BRD typically experience one or more of the following risk factors:

    • Commingling from multiple sale barns/sources
    • Extended transport times and shrink
    • Exposure to wet or cold weather conditions or wide temperature swings
    • Stressful arrival processing procedures (such as castration, dehorning, or branding)
    • Recent weaning and poor vaccination history
    Table 1 Number of punctures tested in the in-use study for the respective vial sizes
    Vial size [mL]Number of punctures tested in the in-use study
    508
    1008
    25016
  • WARNINGS

    WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN.

    Avoid direct contact with skin and eyes. If accidental eye exposure occurs, rinse eyes with clean water. If accidental skin exposure occurs, wash the skin immediately with soap and water. Tildipirosin may cause sensitization by skin contact.

    For technical assistance or to report a suspected adverse reaction, call: 1-800-219-9286.

    For customer service or to request a Material Safety Data Sheet (MSDS), call: 1-800-211-3573.

    For additional Zuprevo™18% information go to www.zuprevo.com.

    For a complete listing of adverse reactions for Zuprevo™18% reported to CVM see: http://www.fda.gov/AnimalVeterinary/SafetyHealth.

    DO NOT USE ZUPREVO 18% IN SWINE. Fatal adverse events have been reported following the use of tildipirosin in swine. NOT FOR USE IN CHICKENS OR TURKEYS.

  • RESIDUE WARNING

    RESIDUE WARNING: Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.
  • PRECAUTIONS

    PRECAUTIONS: The effects of Zuprevo™18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond the slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.

  • CLINICAL PHARMACOLOGY

    CLINICAL PHARMACOLOGY: Similar to other macrolides, tildipirosin inhibits essential bacterial protein biosynthesis with selective binding to ribosomal subunits in a bacteriostatic and time-dependent manner. Tildipirosin may be bactericidal against certain isolates of Mannheimia haemolytica and Pasteurella multocida.

    The following plasma pharmacokinetic (PK) properties of tildipirosin have been observed following a subcutaneous injection at a dose of 4 mg/kg body weight in the neck:

    Table 2 Summary of pharmacokinetic characterization of tildipirosin administered subcutaneously to calves at a dose of 4 mg/kg BW.
    ParameterAverageSD
    Cmax: maximum observed plasma concentration
    Tmax: Time at which Cmax was observed
    AUC0-last: Area under the plasma concentration versus time curve measured from time zero to the last sample with tildipirosin concentrations exceeding the limit of quantification of the analytical method
    AUC0-inf: AUC estimated from time zero to time infinity
    t1/2: Terminal elimination half life
    *
    Value based on all 14 animals
    †
    Value based on 8 animals that were slaughtered at 504 hr post-treatment.
    Cmax (ng/mL)767*284
    Tmax (hr)0.75*0.43
    AUC0-last (hr∙ng/mL)21017†3499
    AUC0-inf (hr∙ng/mL)24934†3508
    t1/2 (hr)210†53

    Due to the extensive partitioning of macrolides into tissues and because of their multi-fold greater concentrations in bronchial fluid relative to that observed in the blood, plasma drug concentrations underestimate concentrations at the site of action1. This is shown for tildipirosin in the following table, where bronchial fluid samples were collected in live, healthy calves, and compared to the concentrations in plasma observed in these same animals:

    Table 3 Bronchial fluid-to-plasma ratio of tildipirosin in non-anesthetized cattle following a subcutaneous injection at a dose of 4 mg/kg body weight in the neck
    Time
    (hours)    		Bronchial fluid (BF) concentration (ng/g)Plasma (P) concentration (ng/mL)BF/P Ratio
    AverageSDAverageSD
    4154389529781.85.20
    102975127924296.712.3
    243448143313653.925.4
    723489171270.729.049.3
    961644202460.229.027.3
    1201619162952.319.930.9
    2401937141627.110.871.5
    3361225168226.19.247.0
    504935103216.81.755.6

    Tildipirosin concentrations in bronchial fluid collected in vivo from non-anesthetized cattle reflect the bacterial exposure to drug concentrations at the site of action.

    1
    Nightingale, C.H. (1997) Pharmacokinetics and pharmacodynamics of newer macrolides. The Pediatric Infectious Disease Journal, 16, 438-443.

    MICROBIOLOGY: Tildipirosin has shown in vitro and in vivo antibacterial activity against the bacteria Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni, three pathogens associated with bovine respiratory disease (BRD).

    The minimum inhibitory concentrations (MICs) of tildipirosin against the indicated BRD pathogens were determined using the methods described in the M31-A2 standard of the Clinical and Laboratory Standards Institute (CLSI) and are shown in Table 4.

    The MICs of tildipirosin were determined for isolates of Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni obtained from two BRD field studies. In both studies, tested isolates of M. haemolytica and P. multocida were obtained from nasopharyngeal swabs taken prior to treatment from all study animals. Tested isolates of H. somni were obtained from nasopharyngeal swabs taken prior to treatment from all study animals and from nasopharyngeal swabs taken from saline-treated animals classified as treatment failures.

    Table 4 Tildipirosin minimum inhibitory concentration (MIC) values* of indicated pathogens isolated from BRD field studies in the U.S.
    Indicated PathogensYear of isolationStudyNumber of isolatesMIC50†
    (μg/mL)    		MIC90†
    (μg/mL)    		MIC range
    (μg/mL)
    *
    The correlation between in vitro susceptibility data and clinical effectiveness is unknown.
    †
    The lowest MIC to encompass 50% and 90% of the most susceptible isolates, respectively.
    Mannheimia haemolytica2007Treatment484120.25 to >32
    2007 to 2008Control178110.25 to >32
    Pasteurella multocida2007Treatment2350.510.12 to >32
    2007 to 2008Control2730.51≤0.03 to 4
    Histophilus somni2007Treatment33241 to 4
    2007 to 2008Control32241 to >32
  • SPL UNCLASSIFIED SECTION

    EFFECTIVENESS: In a multi-location field study, calves with naturally occurring BRD were treated with tildipirosin. The treatment success rate of the tildipirosin-treated group was compared to the treatment success rate in the saline-treated control group. A treatment success was defined as a calf not designated as a treatment failure from Day 1 to 13 and with normal attitude, normal respiration, and a rectal temperature of < 104°F on Day 14. The treatment success rate was significantly higher (p = 0.003) for the tildipirosin-treated group (229/300, 76%) compared to the saline-treated control group (96/200, 32%). There were no BRD-related deaths in the tildipirosin-treated group compared to a 7% (21/300) BRD-related mortality rate in the saline-treated group.

    In another multi-location field study, calves at high risk for developing BRD were administered tildipirosin. The treatment success rate of the tildipirosin-treated group was compared to the treatment success rate in the saline-treated control group. A treatment success was defined as a calf not designated as a treatment failure based on clinical respiratory and attitude scoring and, if necessary, rectal temperature measurement of < 104°F through the end of the study (Day 14). The treatment success rate was significantly higher (p = 0.0001) for the tildipirosin-treated group (305/386, 79%) compared to the saline-treated group (197/387, 51%). There were three BRD-related deaths during the study (one tildipirosin-treated calf and two saline treated calves).

  • SPL UNCLASSIFIED SECTION

    ANIMAL SAFETY: A target animal safety study was conducted using Zuprevo™18% administered in 5-month-old cattle as three subcutaneous doses of 4, 12, or 20 mg/kg BW given 7 days apart (1×, 3×, and 5× the labeled dose). Animals remained clinically healthy during the study at the labeled dose. Injection site swelling and inflammation, initially severe in some animals, was observed that persisted to the last day of observation (21 days after injection). No other drug-related lesions were observed macroscopically or microscopically at the labeled dose.

    A separate injection site tolerance study was conducted using Zuprevo™18% in 5- to 9-month-old cattle administered as a single subcutaneous injection of 10 mL. Injection site swelling and inflammation, initially severe in some animals, was observed that persisted to the last day of observation (35 days after injection). No other drug-related clinical signs were observed.

  • STORAGE AND HANDLING

    STORAGE CONDITIONS: Do not store above 30°C (86°F). Do not freeze. The maximum storage time after first puncture is 28 days at or below 25°C (77°F).

  • HOW SUPPLIED

    HOW SUPPLIED: Zuprevo™18% is supplied in 50, 100 and 250 mL, amber glass, sterile, multi-dose vials.

  • SPL UNCLASSIFIED SECTION

    U. S. Patent: 6,514,946

    Approved by FDA under NADA # 141-334
    Use Only as Directed
    Copyright © 2011, 2019 Intervet Inc., a subsidiary of Merck & Co.
    All rights reserved.
    Rev. 02/2019
    Tildipirosin (active ingred.) made in Switzerland. Formulated in Germany.
    Distributed by: Intervet Inc d/b/a Merck Animal Health, Madison, NJ 07940

  • PRINCIPAL DISPLAY PANEL - 100 mL Vial Carton

    ZUPREVO™ 18%
    (Tildipirosin)
    180 mg/mL

    Injectable Solution for Cattle
    Antimicrobial Drug

    FOR SUBCUTANEOUS INJECTION IN BEEF AND
    NON-LACTATING DAIRY CATTLE ONLY.
    NOT FOR USE IN FEMALE DAIRY CATTLE
    20 MONTHS OF AGE OR OLDER OR IN CALVES
    TO BE PROCESSED FOR VEAL.

    100 mL Multiple-Dose Vial
    Sterile

    CAUTION: Federal (USA) law restricts this drug to use
    by or on the order of a licensed veterinarian.

    Approved by FDA under NADA # 141-334

    MERCK
    Animal Health

    PRINCIPAL DISPLAY PANEL - 100 mL Vial Carton
  • INGREDIENTS AND APPEARANCE
    ZUPREVO 
    tildipirosin injection, solution
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:0061-4321
    Route of AdministrationSUBCUTANEOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Tildipirosin (UNII: S795AT66JB) (Tildipirosin - UNII:S795AT66JB) Tildipirosin180 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    Citric acid monohydrate (UNII: 2968PHW8QP)  
    Propylene glycol (UNII: 6DC9Q167V3)  
    Water (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0061-4321-0150 mL in 1 VIAL, MULTI-DOSE
    2NDC:0061-4321-02100 mL in 1 VIAL, MULTI-DOSE
    3NDC:0061-4321-03250 mL in 1 VIAL, MULTI-DOSE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NADANADA14133405/01/2012
    Labeler - Merck Sharp & Dohme Corp. (001317601)
    Establishment
    NameAddressID/FEIBusiness Operations
    Intervet International GMBH328855635MANUFACTURE
    Establishment
    NameAddressID/FEIBusiness Operations
    Lonza AG480007517API MANUFACTURE
View All Sections

Find additional resources

(also available in the left menu)

Safety

Report Adverse Events (Animal Drug), FDA Safety Recalls (Animal Drug)

Related Resources

Clinical Trials

More Info on this Drug

Get Label RSS Feed, View NDC Code(s)NEW!